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Original Research
Impact of Platelet-Rich Plasma
on Arthroscopic Repair of Small-
to Medium-Sized Rotator Cuff Tears
A Randomized Controlled Trial
Richard Holtby,*† MB, BS, FRCSC, Monique Christakis,‡§ MD, FRCPC, Eran Maman,|| MD,
Joy C. MacDermid,{# PT, PhD, Tim Dwyer,†** MBBS, FRACS, FRCSC, PhD,
George S. Athwal,#†† MD, FRCSC, Kenneth Faber,#†† MD, MHPE, FRCSC,
John Theodoropoulos,†** MD, MSc, FRCSC, Linda J. Woodhouse,‡‡§§ PT, PhD,
and Helen Razmjou,||||{{## PT, PhD
Investigation performed at the Holland Orthopedic and Arthritic Centre,
Sunnybrook Health Sciences Centre and Mount Sinai Hospital, Toronto, Ontario, Canada
Background: Increased interest in using platelet-rich plasma (PRP) as an augment to rotator cuff repair warrants further
investigation, particularly in smaller rotator cuff tears.
Purpose: To examine the effectiveness of PRP application in improving perioperative pain and function and promoting healing at
6 months after arthroscopic repair of small- or medium-sized rotator cuff tears.
Study Design: Randomized controlled trial; Level of evidence, 1.
Methods: This was a double-blinded randomized controlled trial of patients undergoing arthroscopic repair of partial- or full-
thickness rotator cuff tears of up to 3 cm who were observed for 6 months. Patients were randomized to either repair and PRP
application (study group) or repair only (control group) groups. The patient-oriented outcome measures utilized were the visual
analog scale (VAS), the Short Western Ontario Rotator Cuff Index (ShortWORC), the American Shoulder and Elbow Surgeons
(ASES) form, and the Constant-Murley Score (CMS). Range of motion (ROM) and inflammatory and coagulation markers were
measured before and after surgery. Magnetic resonance imaging was used at 6 months to assess retear and fatty infiltration rate.
Results: Eighty-two patients (41 males) with a mean age of 59 ± 8 years were enrolled; 41 patients were included in each group.
Both the PRP and control groups showed a significant improvement in their pain level based on the VAS within the first 30 days
(P < .0001), with the PRP group reporting less pain than the control group (P¼ .012), which was clinically significantly different from
days 8 through 11. The PRP group reported taking less painkillers (P ¼ .026) than the control group within the first 30 days. All
outcome measure scores and ROM improved significantly after surgery (P < .0001), with no between-group differences. No dif-
ferences were observed between groups in inflammatory or coagulation marker test results (P > .05), retear (14% vs 18% full
retear; P ¼ .44), or fatty infiltration rate (P ¼ .08).
Conclusion: The PRP biological augmentation for repair of small- to medium-sized rotator cuff tears has a short-term effect on
perioperative pain without any significant impact on patient-oriented outcome measures or structural integrity of the repair
compared with control group.
Keywords: platelet-rich plasma; healing; rotator cuff
Advances in rotator cuff (RC) surgery, such as improved
implants and sutures to secure the repair, have enhanced
the initial strength of repairs done arthroscopically.
However, despite reduced pain and improved function, a
significant incidence of residual or recurrent cuff tears
ranging from 11% to 40% after surgery remains a
concern.14,16,18,33 Although failure of the repair may be
attributed to age, tear size, tendon quality, and repair tech-
niques, intrinsic factors that affect healing are of interest to
clinicians. Recent interest in using biologic augmentation
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to improve the healing process of the repaired RC tendons
has led to an explosion of data on the use of platelet-rich
plasma (PRP).2,15,19,25,39 The healing potential of PRP has
been attributed to the release of multiple growth factors
that have been identified as playing key roles in tendon
healing at the repair site.10,23 These biologically active
growth factors work by stimulating angiogenesis, epitheli-
alization, cell differentiation-replication-proliferation,
and the formation of extracellular matrix and fibrovascular
callus and have the potential to improve tendon regenera-
tion.21,23 In addition, platelets influence the early phases of
the healing process, which allows mechanical stimulation
to start driving neotendon development at an earlier time
point.38 This may have an impact on tendon quality, reduc-
ing retear size and increasing the likelihood of a more suc-
cessful repair.
Recent systematic reviews have concluded that using PRP
at the time of arthroscopic RC repair does not universally
improve retear rates or affect clinical outcome scores.3,32,40,41
However, patients with small- or medium-sized RC tears
appear to show better outcomes with PRP than without
it.3,37 Further investigation of the PRP efficacy and impact
on perioperative pain, functional outcome, and structural
integrity of the RC repair is therefore warranted.
The purpose of this study was to examine the effective-
ness of PRP application in improving perioperative pain
and function and promoting healing after arthroscopic
repair of small- and medium-sized RC tears through a ran-
domized controlled study. Group differences in inflamma-
tory and coagulation markers and adverse events were also
examined. We hypothesized that patients who receive PRP
would have less perioperative pain with better range of
motion and fewer retears detected by magnetic resonance




This was a prospective, double-blinded randomized con-
trolled trial. The target population was patients undergo-
ing arthroscopic RC repair of partial- or full-thickness tears
of up to 3 cm from March 2011 to September 2014.
Considering lack of difference in outcomes reported by pre-
vious investigators,2,19,39 patients were observed for
6 months, and the rate of revision was monitored for 1 year
after surgery.
In addition to informed consent, the inclusion criteria
included age 18 years and a diagnosis of partial- (>50%
cuff thickness) or full-thickness RC tear of3 cm diagnosed
by MRI and confirmed on arthroscopic assessment. Exclu-
sion criteria were inability to speak or read English, previ-
ous surgery of the affected shoulder, evidence of infection,
underlying metabolic or inflammatory disease, avascular
necrosis, adhesive capsulitis, concurrent pathology of sub-
scapularis, superior labral anterior and posterior (SLAP) or
Bankart lesions requiring repair, bone marrow pathology,
abnormal platelet count, serum hemoglobin concentration
<11 g/dL or hematocrit <34%, use of systemic steroids, cur-
rent use of anticoagulants, use of an investigational drug
and/or blood donation within the previous 3 months prior to
surgery, and psychiatric illness that precluded informed
consent. Approval for use of human subjects was obtained
from the Research Ethics Board of the Sunnybrook Health
Sciences Centre. The clinical trials.gov identifier was
NCT01000935.
Clinical and Laboratory Tests
Patient history, including mechanism of injury and symp-
tom characteristics, was documented at approximately 2 to
3 weeks prior to surgery. Objective clinical examination
included range of motion (ROM) prior to surgery and at 6
weeks and 3 and 6 months after surgery. ROM involved
active and passive flexion, abduction, external rotation in
neutral, and internal rotation at 90 of abduction. Active
ROM was not collected at 6 weeks to avoid stressing the
repair. Preoperative level of comorbidity (0-52) was calcu-
lated as continuous data based on a validated score, the
Cumulative Illness Rating Scale,7 which examines the
overall health. In this scale, 0 represents no impairment
and 52 represent the highest level of possible impairment.
Clinical laboratory tests examined inflammatory and
coagulation markers pre- and postoperatively and included
white blood cell count (WBC), hemoglobin (Hb), hematocrit
(HCT), platelet count, hemoglobin A1c (HbA1c), and proin-
flammatory markers: C-reactive protein (CRP) and partial
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thromboplastin time (PTT). These tests were conducted
preoperatively and at 6 weeks. Patients were monitored for
any adverse effect (eg, infection, stiffness) or laboratory
abnormalities. The Data and Safety Monitoring Board
(DSMB) monitored adverse events and provided evalua-
tions of the safety-related events throughout the study for
occurrence of any undesirable events (ie, significant
changes in laboratory values and clinical, surgical, or reha-
bilitation results).
Patient-Oriented Outcome Measures
Preoperative medication consumption related to acetamin-
ophen, nonsteroidal anti-inflammatory drugs (NSAIDS),
and narcotics was documented as yes or no. Postopera-
tively, patients were asked to complete a pain diary using
a visual analog scale (VAS)11,36 and a medication diary
every day from day 1 to day 30 at a specific time. Postoper-
atively, type and number of pills taken was documented on
the medication diary.
Shoulder-related measures consisted of the Short
Western Ontario Rotator Cuff (WORC) Index,28 the
American Shoulder and Elbow Surgeons (ASES) form,29
and the Constant-Murley Score (CMS).6 The ASES and
ShortWORC were collected preoperatively and again at 6
weeks and 3 and 6 months after surgery. The CMS was
not collected at 6 weeks as it was not feasible to perform
the strength component at that time. The strength com-
ponent of the CMS was measured using a simple tensi-
ometer with the shoulder at 90 of elevation in the plane
of the scapula and the elbow extended while the clinician
pulled down on the tensiometer. The maximum pain-free
force that the patient could resist for 5 seconds as the
examiner pulled down on the device was measured. All
measures have established reliability and validity for
patients with RC disease.22,26-28,30
Randomization
Randomization was done through a central system, and
groups were balanced for sex using a random permuted
block. The operating surgeon who administered the PRP
treatment was aware of the group allocation. Patients who
met the exclusion criteria (eg, larger tears, concomitant
pathology) were excluded after arthroscopic examination.
Patients and assessors who performed the outcome scores,
ROM, and strength measures were blinded to group
allocation.
Surgical Procedures
This multicenter trial involved 3 orthopaedic surgeons.
Arthroscopic inspection of the shoulder using standard por-
tals was performed to assess intra-articular structures with
the patient in either the lateral decubitus or beach-chair
position according to the surgeon’s preference. The full-
thickness tears were classified as small (<1 cm) and mod-
erate (1-3 cm) based on the largest dimension.8 The tear
edges and the bone at the lateral articular margin were
debrided. Both articular- and bursal-sided tears of >50%
tendon thickness were converted to full-thickness and
repaired. Standard tendon-to-bone repair techniques were
used depending on the tear morphology and mobility.
Single-row repairs were performed in the majority of cases.
Anterior acromioplasty was performed routinely, with
resection of the lateral end of the clavicle if there was evi-
dence of moderate or severe degenerative changes (Collin
grades 3 and 4) in the acromioclavicular (AC) joint.
Application of the Platelet-Rich Plasma (PRP)
This study used the SmartPReP 2 system (Harvest Tech-
nologies Corp). The patient’s blood was drawn prior to the
start of the procedure. The procedure pack was designed to
process 54 mL of whole blood, which produced 7 mL of con-
centrated PRP. The processing disposable (PD) size of
60 mL was used following manufacturers’ instructions.
Eight milliliters of anticoagulant citrate dextrose solution,
solution A (ACD-A), was drawn into a 60-mL syringe, and
after transferring 2 mL of this solution into the white port
of the PD, 54 mL of venous blood was then drawn into the
syringe. The total syringe volume was transferred into the
red port of the PD. Anticoagulant solution (0.1 mL) was
transferred into a process tube in addition to 1.7 mL of the
processing solution. After 60 minutes of incubation, the PD
was put into the SmartPReP 2 System and was spun in the
centrifuge for 14 minutes, separating the blood into 3 frac-
tions. The concentrated plasma was then resuspended with
platelets and kept in a sterile red cup. The autologous
thrombin solution of the process tube was poured into a
clear cup. An applicator system was used to deliver the
platelet concentrate and thrombin solution. Seven millili-
ters of the autologous platelet concentrate (APC) was
drawn with a 10-mL syringe and 2.5 mL of the thrombin
solution was drawn with a 3-mL syringe. Both syringes
were then attached to the applicator tip. A spinal needle
was used to access the surgical site.
Using the lateral portal, the applicator for the PRP was
positioned in between the bone and the repaired RC. The
inflow was then closed and the subacromial space was
drained via the outflow cannula. A fine suction tip set at
very low pressure was used to carefully drain the subacro-
mial space and clear the site of the cuff repair of blood and
fluid. The PRP required approximately 60 seconds in the
connector to transform into a gel before injected to the site
of repair. The PRP was then slowly injected to build a thick
layer of adherent clot filling the tendon-bone interface
beneath the repaired tendon guided by direct vision. Peri-
operative pain management included an interscalene nerve
block for the first 12 to 18 hours followed by oxycodone/
acetaminophen (1-2 tablets every 4 hours) as needed. Other
medications taken as needed were documented in the diary.
Postoperative Rehabilitation
A shoulder immobilizer, removed for shower and exercise,
was applied for 4 weeks. Early active-assisted forward flex-
ion and pendulum motions were initiated on day 1 postop-
eratively. At 4 weeks, external rotation was added. Internal
rotation and submaximal isometric exercises started at
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6 weeks. Strength exercises against resistance were
delayed until 12 weeks postsurgery. A standardized reha-
bilitation program was given to patients to be performed
under supervision of their physical therapist.
Healing and Retear Status
For assessment of tendon healing, anatomic evaluation of
the cuff repair was conducted with use of MRI prior to and
at 6 months after surgery by a senior musculoskeletal-
trained radiologist who was blinded to group allocation.
Patients were imaged in the supine position with their
arm rested in neutral. Postoperative MRI was performed
on a 1.5-T system (General Electric Medical Systems)
using a 15-platform and dedicated GE shoulder surface
coil. Field of view was 13 cm with T1-weighted sagittal
images (600/min), sagittal proton density fast spin-echo
with fat saturation (2000/22.7), axial proton density fast
spin-echo with fat saturation (2000/22.7), coronal oblique
T2-weighted fast spin-echo (2800/83.2), and coronal
oblique proton density fast spin-echo (2000/34) (slice
thickness, 3.0-4.0 mm with 0.5- to 1-mm gap; matrix,
288-320  192-244). Flow compensation and spatial pre-
saturation were routinely employed.
The extent of any retear was determined in the coronal
plane using a system described by Thomazeau et al.35 The
postsurgical tear status was categorized as (1) none,
(2) partial retear, (3) stage I retear (tear edge was lying
over the greater tuberosity [usually <1 cm in greatest diam-
eter]), (4) stage II retear (tear exposed the humeral head
but did not retract to the glenoid articular surface [1-3 cm
in greatest diameter]), and (5) stage III (3-5 cm in greatest
diameter). Biceps tendon status was categorized as normal,
tendonitis, subluxated, dislocated, partial tear, or full tear.
Fatty infiltration was classified on the T1 sagittal image
using the Goutallier fatty index on the most lateral oblique
image in which the spine is seen in contact with the scap-
ular body (Y-shaped view).12 According to this classifica-
tion, stage 0 indicates a muscle with no fat, stage 1
indicates a muscle containing some fatty streaks, stage 2
indicates more muscle than fat, stage 3 indicates as much
fat as muscle, and stage 4 indicates more fat than muscle.
Statistical Analysis
The sample size for a comparative longitudinal study







where N is the number of subjects in each of 2 groups, s is
the pooled standard deviation, effect size4 ¼ (m1  m2)/s ¼
0.2, 0.5, and 0.8 for ‘‘small,’’ ‘‘medium,’’ and ‘‘large’’ effects,
m1  m2 is the difference in means of the 2 groups, n is the
number of time points, and r is the correlation of the
repeated measures. Previously collected data of patients
with RC tear who had undergone arthroscopic repair had a
correlation of 0.12 between preoperative and 6-month
postoperative pain scores, and with a medium effect size of
0.5,4 35 subjects were required in each group. This value was
inflated by 15% to compensate for patients who were lost to
follow-up. Therefore, a minimum of 80 patients were
required to answer the primary research question.
Group differences in preoperative characteristics (side,
mechanism of injury, and symptom characteristics) and
MRI findings were explored using the Fisher exact or chi-
square tests for categorical data as appropriate. The Cumu-
lative Illness Rating Scale was examined with independent
t tests. SAS Proc Mixed repeated-measures analysis of
variance (ANOVA) was used to examine between-group dif-
ferences and overall change in pain and medication use for
30 consecutive days and in disability scores and ROM for 6
months. The pain scores were further examined for clini-
cally meaningful difference if they exceeded 1.4 points, con-
sidered as the minimal clinically important difference
(MCID) reported for patients with RC disease by Tashjian
et al.34 Preoperative and 6-week postoperative laboratory
findings were examined with independent t tests. Statisti-
cal analysis was performed using SAS version 9.1.3 (SAS
Institute). Statistical results are reported using 2-tailed
P values, with significance set at P < .05.
RESULTS
A total of 92 patients met the eligibility criteria, of whom
10 patients were excluded intraoperatively (2 had a large
RC tear, 5 had no RC tear, 2 had a subscapularis repair, 1 had
intubation difficulty that led to cancelation of surgery). There-
fore, 82 patients were included (41 females, 41 males; mean
age± SD,59± 8years; range,38-76years), ofwhom41patients
received PRP. Seventy-three patients had a full-thickness
tear and 9 patients (4 PRP, 5 controls) had a high-grade
partial-thickness tear that required a repair. Figure 1 shows
theprogress of the subjects through thephases of the study.Of
these 82 patients, all completed their 6-week assessment. One
study patient (72-year-old woman) sustained a displaced 3-
part fracture of the proximal humerus of the involved side as
a result of an unrelated fall after the 6-week appointment and
was excluded from further assessment.
Table 1 shows the subgroup analysis of pre- and intraopera-
tive characteristics. There were no statistically significant
differences between groups in terms of age (PRP, 59 years;
control, 59 years), sex (PRP, 21 females/20 males; control,
20 females/21 males), symptom duration (25 vs 29 months),
medication use, type of tear (full- vs partial-thickness), or
medical comorbidity (2.62 vs 3.02). Preoperative pain and
disability scores (ASES, ShortWORC, and CMS) were also
comparable. Of 3 patients with active compensation claims
related to the shoulder, 2 received PRP and 1 did not.
Although the PRP group had 4 patients with stage 1 supra-
spinatus fatty infiltration compared with only 1 patient in the
control group, this was not statistically significantly different.
Adverse Events
No adverse events related to PRP application were noted
during the study. However, 2 patients had intraoperative
4 Holtby et al The Orthopaedic Journal of Sports Medicine
complications: 1 study patient (72-year-old woman) had
decreased oxygen saturation possibly related to pneumonia.
This patient developed shoulder stiffness after surgery. The
second patient was in the control group (57-year-old man)
and developed pulmonary edema. Both patients required
overnight observation and were discharged the next day.
There was no surgical revision at the 1-year time frame.
Patient-Oriented Outcome Measures
Pain Scores. Figure 2 shows the change in VAS score
over time. The repeated-measures ANOVA showed a signif-
icant improvement in pain level within the first 30 days
(F ¼ 34.60, P < .0001). There was a between-group dif-
ference in favor of the PRP group reporting statistically
significantly less pain within this period (F ¼ 6.61, P ¼
.012). There was no time  group interaction (F ¼ 1.35,
P ¼ .10). The difference in pain scores was clinically mean-
ingful only on days 8 through 11, when it exceeded 1.4
points, considered as the MCID.34
Medication Use. Both groups had a statistically signifi-
cant reduction of narcotic and NSAID use over the 30-day
period postoperatively. The PRP group took less acetamin-
ophen over this period, but groups were similar in taking
narcotics and NSAIDs, with no statistically significant
differences between groups (Table 2).
Shoulder-Related Outcome Measures
Both groups showed a significant improvement in their dis-
ability scores over time. There were no statistically
significant differences between groups in ShortWORC or
ASES or CMS over time (Table 3).
Clinical Examination (Range of Motion)
Both groups showed significant improvement in all direc-
tions of range of motion over time. However, no statistically
significant differences were observed between groups.
There was an interaction between passive flexion and
group allocation, indicating that although there were no
overall group differences, the pattern of change was differ-
ent between groups, with the PRP group having better
92 patients eligible 
10 patients excluded  
at surgery 
1 excluded due to  
unrelated humeral fracture 
secondary to a fall 
82 patients available  
for randomization
• 5 no repair required  
• 2 large FTRCT  
• 2 subscapularis 
   tears  
• 1 intubation 
  difficulty 
41 randomized to PRP treatment
41 attended 6-week follow-up 
36 completed MRI 
at 6-month follow-up 
38 attended 3-month follow-up
40 attended 6-month follow-up 
41 randomized to control group 
38 completed MRI 
at 6-month follow-up 
40 attended 3-month follow-up 
35 attended 6-month follow-up 
41 attended 6-week follow-up 
Figure 1. Flowchart of participants. FTRCT, full-thickness









Age, y, mean ± SD 59 ± 8 59 ± 8
Sex, female/male, n 21/20 20/21
Symptom duration, mo, mean ± SD 25 ± 18 29 ± 37
Affected side, right/left, n 26/15 25/16
Comorbidity (0-52), mean ± SDb 2.7 ± 2 3.0 ± 2
Medication use
Painkillers 12 (29) 15 (36)
NSAIDs 12 (29) 9 (22)
Narcotics 4 (10) 4 (10)
Symptoms characteristics
Pain on movement 38 (9) 38 (9)
Night pain 33 (8) 31 (8)
Weakness 31 (8) 34 (8)
Stiffness 26 (6) 26 (6)
Mechanism of injury
Insidious 5 (1) 3 (<1)
Repetitive activities 13 (32) 16 (39)
Fall 8 (20) 7 (20)
Traumatic 13 (32) 7 (20)
Direct blow 2 (<1) 8 (20)
Rotator cuff pathology
Full-thickness tear 37 (90) 36 (88)
Partial-thickness tear 4 (10) 5 (12)
Biceps pathology
None 21 (49) 21 (51)
Partial tear 18 (44) 19 (46)
Full rupture 2 (5) 1 (2)
Associated surgeries
Acromioplasty 41 (100) 41 (100)
Lateral clavicle resection 30 (73) 25 (61)
Biceps tenodesis 2 (5) 2 (5)
Type of fixation
Single-row 39 (95) 36 (87)
Double-row 2 (5) 5 (13)
Number of anchors
1 32 (78) 27 (66)
2 9 (22) 14 (34)
aData are presented as n (%) unless otherwise indicated. No
statistically significant differences were detected between groups.
NSAIDs, nonsteroidal anti-inflammatory drugs; PRP, platelet-rich
plasma.
bBased on the Cumulative Illness Rating Scale7 (0 ¼ no impair-
ment, 52 ¼ highest level of possible impairment).
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passive flexion at 6 weeks but not at other time points
(Table 3).
Laboratory Tests
No group differences were observed in general blood tests or
coagulation marker test results (P > .05), indicating that use
of PRP did not introduce any detectable coagulation or
inflammatory response at 6 weeks postoperatively (Table 4).
Postsurgical Retear
MRIs of 74 patients were available for review (36 PRP, 38
control). Table 5 shows the retear rate in each group.
Although the PRP group had more complete healing
(23/36 vs 18/38), with a smaller number of partial- (8/36
vs 13/38) and full-thickness retears (5/36 vs 7/38), this was
not statistically significant.
Fatty infiltration of muscle remained unchanged in all
those who had a preoperative stage 2 (more muscle than
fat) or stage 3 (as much muscle as fat) score regardless of
the treatment they received (PRP vs no PRP). Therefore,
use of PRP did not improve the fatty infiltration status.
However, 3 patients in the control group improved from
stage 1 or 2 to stage 0. Fatty infiltration in 4 patients in
the study group with stage 1 did not improve (Table 5).
DISCUSSION
The present study confirms the findings of previous studies
on use of PRP injection in patients with small- to medium-
sized RC tears2,19,39 with respect to lack of differences in
disability, retear rate, and fatty infiltration. The only clin-
ically significant difference was the PRP group having less
pain from day 8 through day 11.
In a similar study to ours, Castricini et al2 examined
88 patients with small- to medium-sized RC tears random-
ized to arthroscopic double-row repair with or without autol-
ogous platelet-rich fibrin matrix (PRFM) augmentation. At
16 months’ follow-up, no significant difference was found in
the CMS or MRI findings, which was based on tendon thick-
ness, coverage of greater tuberosity, and intensity of signal.
Their study did not support the use of PRFM to improve


















Figure 2. Daily comparison of group visual analog scale (VAS) pain scores (range, 0-10) for the first 30 days. Group differences
(PRP vs control) were statistically and clinically significant from days 8 through 11. PRP, platelet-rich plasma.
TABLE 2
Postoperative Medication Use (Days 1-30)a
Variable Between-Group Difference Within-Group Change Time  Group Interaction
Acetaminophen F ¼ 5.13, P ¼ .026 F ¼ 1.11, P ¼ .308 F ¼ 0.58, P ¼ .97
NSAIDs F ¼ 0.00, P ¼ .98 F ¼ 1.57, P ¼ .026 F ¼ 1.45, P ¼ .06
Narcotics F ¼ 3.28, P ¼ .07 F ¼ 47.26, P < .0001 F ¼ 1.20, P ¼ .21
aNSAIDs, nonsteroidal anti-inflammatory drugs.
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Of 88 participants, MRI results were available for 78
(38/40). In 5 patients, there was MRI evidence of a retear:
4 patients in the control group (10.5%) and 1 (2.5%) in the
PRP group (P ¼ .07). None of the patients required further
treatment.
In another prospective, randomized, double-blinded
study of 54 patients by Malavolta et al,19 full-thickness
supraspinatus tears of less than 3 cm were subjected to
arthroscopic single-row repair. The outcomes were assessed
by the University of California at Los Angeles (UCLA)
scores, CMS, and VAS for pain. MRI was performed before
surgery and repeated at 3, 6, 12, and 24 months after sur-
gery. Both groups of patients exhibited significant clinical
improvement (P < .001). Similar to our study, the investi-
gators did not find any group differences in the UCLA,
CMS, and VAS scores at 2 years postoperatively. The only
difference was in UCLA scores at 12 months (30 in the
control group and 32 in the PRP group; P ¼ .046), which,
if adjusted for multiple comparisons, would not be consid-
ered significant. In their study, the control group exhibited
1 case of a complete retear and 4 partial retears, and the
PRP group exhibited 2 cases of partial retears. Although,
the incidence of partial retears was 2-fold greater in the
control group at the 6- and 12-month assessments com-
pared with the PRP group, this was not statistically signif-
icant (P ¼ .42). In our study, we had a greater incidence of
partial and full retears (22% partial and 14% full retear in
PRP vs 34% partial and 18% full retear in control), which
may potentially be related to the older patients included in
our study (59 years vs 54/55 years). We did find a trend
toward a lower retear rate in the PRP group, which could
be related to the impact of active growth factors being
released at the repair site. However, this difference was not
statistically significant.
Similar to our study, Weber et al,39 who randomized
60 patients with RC tears (mean size, 1.77 and 1.72 cm in
the PRP and control groups, respectively) to PRFM
reported that PRFM did not significantly improve clinical
outcomes based on UCLA score at 12 months postoperative.
Their retear rate was not statistically significant between
groups (12/29 [43%] in the control vs 7/30 [30%] in the
PRFM group).
The information on perioperative pain is more controver-
sial. We found that pain was statistically significantly less
during the first 30 days in the study group, being clinically
different on days 8 through 11. Malavolta et al,19 who
assessed postoperative pain on days 1 and 7 and at 3, 6,
and 12 months, revealed no statistically significant
between-group differences. Weber et al39 reported no group
differences in perioperative pain on arrival to the recovery
room or at 1 hour after surgery, which is similar to our
findings of no group differences in VAS for at least 4 days
after surgery. In the study by Randelli et al,25 who included
small to massive tears, the PRP group showed a statisti-
cally significant reduction of VAS score as soon as day 3
after surgery (P ¼ .04), which is more in line with our find-
ings. Using a standardized pain diary is expected to have
provided a more consistent picture of pain fluctuation dur-
ing the first month after surgery, and overall, it appears
that the PRP does not improve pain immediately on post-
operative day 1 but has the potential to provide a short-
term superior pain reduction.
The main growth factors in PRP are transforming
growth factor b1 (TGFb1), platelet-derived growth factor
(PDGF), vascular endothelial growth factor (VEGF), hepa-
tocyte growth factor (HGF), and insulin-like growth factor 1
(IGF1). The platelets are believed to synthesize and secrete
additional factors for 7 to 10 days after the initial release of
growth factors, which coincides with the inflammatory and
TABLE 3
Shoulder-Related Disability Scores








ASES F1 ¼ 1.39, P ¼ .24
Preop 57 ± 19 52 ± 19 F2 ¼ 78.63, P < .0001
Final postop 86 ± 18 84 ± 18 F3 ¼ 0.32, P ¼ .81
ShortWORC F1 ¼ 1.83, P ¼ .18
Preop 42 ± 19 35 ± 22 F2 ¼ 103.01, P < .0001
Final postop 85 ± 21 79 ± 27 F3 ¼ 0.12, P ¼ .95
CMS F1 ¼ 0.30, P ¼ .58
Preop 65 ± 19 61 ± 23 F2 ¼ 112.66, P < .0001
Final postop 108 ± 19 103 ± 24 F3 ¼ 0.22, P ¼ .81
Range of motion, deg
Flexion: active F1 ¼ 1.39, P ¼ .24
Preop 143 ± 31 139 ± 33 F2 ¼ 14.17, P < .0001
Final postop 170 ± 12 155 ± 24 F3 ¼ 0.29, P ¼ .75
Flexion: passive F1 ¼ 3.5, P ¼ .0.06
Preop 158 ± 16 159 ± 19 F2 ¼ 103.59, P < .0001
Final postop 164 ± 20 162 ± 18 F3 ¼ 3.33, P ¼ .02
Abduction: active F1 ¼ 1.45, P ¼ .23
Preop 134 ± 37 129 ± 9 F2 ¼ 15.50, P < .0001
Final postop 160 ± 24 150 ± 28 F3 ¼ 0.15, P ¼ .86
Abduction: passive F1 ¼ 0.50, P ¼ .48
Preop 150 ± 28 150 ± 25 F2 ¼ 12.11, P < .0001
Final postop 166 ± 18 157 ± 23 F3 ¼ 1.34, P ¼ .26
External rotation:
active
F1 ¼ 0.00, P ¼ .95
Preop 54 ± 17 57 ± 13 F2 ¼ 6.86, P ¼ .001
Final postop 63 ± 16 67 ± 12 F3 ¼ 0.76, P ¼ .47
External rotation:
passive
F1 ¼ 0.32, P ¼ .57
Preop 64 ± 16 62 ± 23 F2 ¼ 62.25, P < .0001
Final postop 71 ± 65 69 ± 62 F3 ¼ 1.46, P ¼ .23
Internal rotation:
active
F1 ¼ 1.12, P ¼ .29
Preop 39 ± 19 37 ± 23 F2 ¼ 14.23, P < .0001
Final postop 56 ± 15 47 ± 18 F3 ¼ 1.28, P ¼ .28
Internal rotation:
passive
F1 ¼ 1.89, P ¼ .17
Preop 52 ± 19 51 ± 22 F2 ¼ 77.58, P < .0001
Final postop 66 ± 17 61 ± 16 F3 ¼ 0.63, P ¼ .53
aData are presented as mean ± SD. ANOVA, analysis of vari-
ance; ASES, American Shoulder and Elbow Surgeons; CMS,
Constant-Murley score; postop, postoperative; preop, preoperative;
PRP, platelet-rich plasma; ShortWORC, Short Western Ontario
Rotator Cuff Index.
bF values provided for (1) between-group differences, (2) within-
group differences, and (3) time  group interaction.
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repair phases of tendon healing.13,21 The role of autolo-
gous growth factors in pain reduction through increased
tendon cell proliferation, collage synthesis, or vasculari-
zation within the first few days after surgery should be
considered.13,21,42
Consistent with previous work, our results suggest that
PRP augmentation for small- to medium-sized RC tears
does not show significant improvement in patient-
oriented outcome measures or repair integrity when com-
pared with a conventional repair. At short-term follow-up,
patients managed with PRP-augmented repair showed
better control of postoperative pain. The subjective
improvement in pain and disability after repair of
the RC tendons is impressively high despite failure to
achieve a full repair and the variable rate of structural
healing.5,17,20,24,31 In light of no between-group differences
in flexion, the interaction between passive flexion and
group allocation also does not appear to be clinically sig-
nificant as it does not correlate with active flexion or
other range of motion directions. In a systematic review
of studies published between 2010 and 2014 to assess
effectiveness, safety, and cost-effectiveness of PRP aug-
mented repair, Vavken et al37 reported lower retear rate
in favor of PRP use in the subsample of patients with
small- to medium-sized tears (P ¼ .038). These findings
were predominantly based on 3 studies that included
small to massive tears,1,15,25 of which only 1 study was a
randomized controlled study.25 Chahal et al3 added
another randomized controlled trial and calculated the
lower risk of retear in favor of PRP (P ¼ .006). Of interest,
Vavken et al37 conducted a unique cost analysis and
reported that the use of PRP was not cost-effective for
TABLE 4
General Blood Test Resultsa
Variable PRP Group Control Group Statistics
WBC count, 109/L
Preop 6.5 ± 1.50 6.28 ± 1.84 t ¼ 0.62, P ¼ .54
6 weeks postop 6.8 ± 1.86 6.41 ± 1.72 t ¼ 0.97, P ¼ .34
Hemoglobin (Hb), g/L
Preop 142.8 ± 10 143.3 ± 14 t ¼ 0.18, P ¼ .86
6 weeks postop 144.4 ± 9 143.2 ± 12 t ¼ 0.48, P ¼ .63
Hematocrit
Preop 0.42 ± 0.03 0.43 ± 0.04 t ¼ 0.18, P ¼ .86
6 weeks postop 0.42 ± 0.03 0.43 ± 0.05 t ¼ 0.74, P ¼ .46
Platelet count, 109/L
Preop 231.5 ± 65 245 ± 61 t ¼ 0.96, P ¼ .34
6 weeks postop 235.1 ± 55 243.9 ± 65 t ¼ 0.63, P ¼ .53
A1c (HbA1c), %
Preop 5.5 ± 0.03 5.5 ± 0.03 t ¼ 1.64, P ¼ .10
6 weeks postop 5.8 ± 0.07 5.7 ± 0.06 t ¼ 1.64, P ¼ .10
C-reactive protein
Preop 2.35 ± 2.5 2.70 ± 2.96 t ¼ 1.21, P ¼ .23
6 weeks postop 2.51 ± 2.7 3.37 ± 3.4 t ¼ 0.53, P ¼ .60
Partial thromboplastin time, s
Preop 30.65 ± 3 30.46 ± 2 t ¼ 0.31, P ¼ .75
6 weeks postop 31.21 ± 3 31.17 ± 2 t ¼ 0.06, P ¼ .95
aData are presented as mean ± SD. Hb, hemoglobin; HbA1c, glycated hemoglobin; postop, postoperative; preop, preoperative; PRP,
platelet-rich plasma; WBC, white blood cell.
TABLE 5






Retearb FTE ¼ 0.007, P ¼ .44
None 23 (64) 18 (47)
Partial 8 (22) 13 (34)
Full 5 (14) 7 (18)
Stage I 4 (11) 4 (11)
Stage II 1 (3) 3 (8)
Stage III 0 0
Fatty infiltrationc FTE ¼ 0.02, P ¼ .22
Preoperative
Stage 0 26 (72) 29 (77)
Stage 1 5 (14) 7 (18)
Stage 2 4 (11) 1 (3)
Stage 3 1 (3) 0
Postoperative FTE ¼ 0.005, P ¼ .08
Stage 0 26 (72) 33 (87)
Stage 1 5 (15) 5 (13)
Stage 2 4 (12) 0
Stage 3 1 (3) 0
aData are presented as n (%). FTE, Fisher exact test; MRI,
magnetic resonance imaging; PRP, platelet-rich plasma.
bClassified according to Thomazeau et al35: stage I tear ¼ usu-
ally <1 cm in greatest diameter, stage II tear ¼ 1-3 cm in greatest
diameter, stage III tear ¼ >5 cm in greatest diameter.
cAccording to Goutallier fatty index: stage 0 ¼ no fat, stage 1 ¼
some fatty streaks, stage 2 ¼ more muscle than fat, stage 3 ¼ as
much fat as muscle, and stage 4 ¼ more fat than muscle.
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small- and medium-sized tears in spite of fewer retears.
The cost-effectiveness analysis was based on an incremen-
tal ratio of US$127,893 per quality-adjusted life year
gained, assuming a 5% revision rate. It is of value to note
that small defects detected on MRI postoperatively do not
predictably correlate with clinical outcomes5,17,20,24,31 and
are not always subject to a revision surgery.
Intraoperative PRP injections do not change outcomes or
retear rate, and the short-lived improved perioperative
pain (days 8-11) does not justify the cost, increased chance
of infection, or added operative time and should not be
encouraged in small- to medium-sized tears. Identifying
treatments and techniques that improve the structural
integrity of RC repairs remains a clinical challenge and
deserves ongoing investigation.
A limitation of the present study is that the number of
platelets and levels of growth factors injected at the time of
surgery were not measured. Future studies that incorpo-
rate this information will help to better determine the
amount of the growth factors released within the RC repair.
There was also no intertester reliability on rating of the
retears due to involvement of only 1 musculoskeletal-
trained radiologist. Our follow-up period was relatively
short. The final follow-up with subjective outcomes and
MRI examination was at 6 months after surgery, and rate
of revision was examined at 1 year after completion of
study. Considering the differences in subjective measures
equalized at 6 months and the similarity of our results with
previous studies, longer follow-up would not have had a
significant impact on our conclusions. This study was con-
ducted at academic centers with subspecialty trained mus-
culoskeletal surgeons and radiologists, which limits the
generalizability of the results.
CONCLUSION
The PRP biological augmentation for repair of small- to
medium-sized RC tears has a short-term effect on peri-
operative pain, without any significant impact on patient-
oriented outcome measures or structural integrity of the
repair compared with a control group.
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